Purpose: In prior analyses we observed that the achievable patency rate after vasectomy reversal is a key factor in whether reversal surgery is more cost-effective than in vitro fertilization-intracytoplasmic sperm injection for fertility after vasectomy. Because pregnancies will occur sooner with an earlier time to patency, this clinical parameter becomes important with advanced maternal age. We hypothesize that there are predictors of time to patency after reversal that are valuable for patient counseling and intraoperative decision making in cases of advanced maternal age.
Materials And Methods: We retrospectively reviewed a cohort of consecutive men who underwent vasectomy reversal. Data obtained included patient demographics, semen analyses, intraoperative findings, patency rates and time to achieve patency.
Results: A total of 150 patients met the inclusion criteria. Mean patient age was 42.9 years (range 27 to 61) and mean followup was 12.5 months (range 1 to 90). The presence of motile sperm in vasa predicted faster patency rates postoperatively. Of patients with motile sperm 95% achieved patency by 6 months whereas 76% of patients without motile sperm achieved patency within 6 months (p = 0.04). An obstructive interval of 8 years or less and undergoing vasovasostomy instead of epididymovasostomy predicted faster time to patency within the first 3 months after reversal. Patient age was not associated with time to patency after bilateral vasovasostomy.
Conclusions: Motile sperm found intraoperatively at the testicular vas, undergoing vasovasostomy and an obstructive interval of 8 years or less predict shorter time to patency after vasectomy reversal. Patient age does not appear to affect patency kinetics after reversal. Patient counseling regarding fertility after vasectomy may benefit from this information especially in the setting of advanced maternal age.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.juro.2007.01.158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Direct-to-consumer semen analysis products: Content, accountability, and adherence to clinical guidelines.
Andrology
January 2025
Department of Urology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Background: Direct-to-consumer (DTC) semen analysis (SA) products obviate barriers that deter men from clinic testing and have made strides in providing higher quality data. However, it is unclear how well these products adhere to the 2021 WHO guidelines on examination and processing of human spermatozoa as they pertain to the evaluation of male fertility.
Objective: We investigate the content and adherence to clinical guidelines associated with consumer-facing information on DTC analysis products.
Short and long-term effects of experimental varicocele.
Andrology
January 2025
Department of Surgery, Division of Urology, Human Reproduction Section, São Paulo Federal University, São Paulo, Brazil.
Background: Varicocele is associated with a progressive decrease in male fertile potential, but it has yet to be determined if the duration of varicocele is associated with altered sperm functional quality.
Objectives: This experimental study investigated the time-dependent effects of varicocele on spermatogenesis, sperm parameters, and sperm functional traits.
Materials And Methods: Thirty-five mature male Wistar rats (200 ± 25 g) were included.
Unseen Threats: The Long-term Impact of PET-Microplastics on Development of Male Reproductive Over a Lifetime.
Adv Sci (Weinh)
January 2025
Department of Food Science and Nutrition, Pukyong National University, Busan, 48513, Republic of Korea.
The physical abrasion of plastics from simple everyday entered the food chain, with associated risks recently emphasized. Although many studies have reported the adverse effects of microplastics (MPs) on human, the reproductive implications of continuous exposure to physically abraded polyethylene terephthalate (PET)-MPs remain unexplored. Ingestion of physically abraded PET-MPs (size range: 50-100 µm) in mice from 5 to 34 weeks of age at an annual intake relevant dose of MPs (5 mg week) significantly impaired male reproductive function.
View Article and Find Full Text PDFA Case-Control Study of the Association Between Gene Polymorphisms (rs1695 and rs1138272) and the Susceptibility to Male Infertility in the Moroccan Population.
Genet Test Mol Biomarkers
January 2025
Laboratory of Genomics and Human Genetics, 1, Place Louis Pasteur, Institut Pasteur du Maroc, Casablanca, Morocco.
Infertility affects 10-15% of couples worldwide, with male factors accounting for half of cases. Environmental, behavioral, and genetic problems contribute to spermatogenic failure in 30% of idiopathic male infertility cases. Other factors, such as oxidative stress (OS), cause impaired spermatogenesis, abnormal sperm morphology, and reduced motility, eventually triggering male infertility.
View Article and Find Full Text PDFEvaluation of the impact of on the testis of cisplatin-treated albino rats: Biochemical, histopathological, and ultrastructural study.
Histol Histopathol
December 2024
Department of Evaluation of Natural Resources, Environmental Studies and Research Institute, University of Sadat City, Egypt.
Cisplatin is an antineoplastic drug that exhibits toxicity dependent on dosage and has adverse reproductive effects. (Bitter melon) is a natural vegetable plant; its active ingredients possess antioxidant, apoptotic, antiproliferative, hypoglycemic, and other therapeutic properties. This study evaluates the effect of the administration of bitter melon extract, cisplatin, and cisplatin/bitter melon cotreatment on liver and kidney functions, serum and testicular oxidative status, testis histology, and sperm parameters.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!